Health economic assessment of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer

被引：3
作者：
Annemans, L
Moeremans, K
Lamarque, H
机构：
[1] State Univ Ghent, HEDM, Meise, Belgium
[2] Astrazeneca, Rueil Malmaison, France
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61604-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：625 / 625
页数：1
相关论文
共 50 条
  • [31] Intermittent letrozole as adjuvant treatment in postmenopausal hormone-receptor positive early breast cancer patients
    Balduzzi, A.
    Bagnardi, V.
    Volpe, S.
    Cancello, G.
    Iorfida, M.
    Dellapasqua, S.
    Sandri, M.
    Goldhirsch, A.
    Colleoni, M.
    CANCER RESEARCH, 2013, 73
  • [32] Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21).
    Braun, S.
    Naume, B.
    Mueller, E.
    Janni, W.
    Marth, C.
    Gnant, M. F.
    CANCER RESEARCH, 2009, 69 (02) : 297S - 298S
  • [33] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
    Boccardo, F.
    Rubagotti, A.
    Guglielmini, P.
    Fini, A.
    Paladini, G.
    Mesiti, M.
    Rinaldini, M.
    Scali, S.
    Porpiglia, M.
    Benedetto, C.
    Restuccia, N.
    Buzzi, F.
    Franchi, R.
    Massidda, B.
    Distante, V.
    Amadori, D.
    Sismondi, P.
    ANNALS OF ONCOLOGY, 2006, 17 : VII10 - VII14
  • [34] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer.
    Delea, T. E.
    Karnon, J.
    Sofrygin, O.
    Thomas, S. K.
    Barghout, V
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S116 - S117
  • [35] Comparison of the efficacy of adjuvant letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.
    Sendur, Mehmet Ali Nahit
    Aksoy, Sercan
    Altundag, Kadri
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Comparison of the cost-effectiveness of upfront letrozole or anastrozole versus tamoxifen for early breast cancer in hormone receptor positive (HR plus ) postmenopausal women the Cypriot perspective
    Andreopoulos, D.
    Karnon, J.
    Kaura, S.
    EJC SUPPLEMENTS, 2008, 6 (07): : 126 - 127
  • [37] Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
    Smith, Ian
    Yardley, Denise
    Burris, Howard
    De Boer, Richard
    Amadori, Dino
    McIntyre, Kristi
    Ejlertsen, Bent
    Gnant, Michael
    Jonat, Walter
    Pritchard, Kathleen I.
    Dowsett, Mitch
    Hart, Lowell
    Poggio, Susan
    Comarella, Lisa
    Salomon, Herve
    Wamil, Barbara
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1041 - +
  • [38] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
    Johnston, Stephen R. D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
  • [39] Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer - a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
    Lux, Michael P.
    Woeckel, Achim
    Benedict, Agnes
    Buchholz, Stefan
    Kreif, Noemi
    Harbeck, Nadia
    Kreienberg, Rolf
    Kaufmann, Manfred
    Beckmann, Matthias W.
    Jonat, Walter
    Hadji, Peyman
    Distler, Wolfgang
    Raab, Guenther
    Tesch, Hans
    Weyers, Georg
    Possinger, Kurt
    Schneeweiss, Andreas
    ONKOLOGIE, 2010, 33 (04): : 155 - 166
  • [40] Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer
    Khan, Q. J.
    Barr, J. A.
    Britt, A. S.
    Kimler, B. F.
    Connor, C. S.
    McGinness, M.
    Mammen, J. M. V.
    Wagner, J. L.
    Amin, A.
    Springer, M.
    Baccaray, S.
    Fabian, C. J.
    Sing, A. P.
    Sharma, P.
    CANCER RESEARCH, 2016, 76
12345